Scimitar Equity Blog

Osiris (OSIR) Prochymal approved in Canada

Henry McCusker — Thu, 17 May 2012 23:57:22 +0000

The 1st regulatory approval of a stem-cell drug in the world as Stem cell treatment gets limited approval in Canada Health Canada, regulators approved its stem cell therapy Prochymal, which is intended to treat a deadly side effect of bone marrow transplants for which steroids haven’t worked. Steroids have a 30-50% success rate, and [...]

RegMed Daily, Closing Bell, 5/17/12, The sector is so bad, I wake up every hour each night and cry

Henry McCusker — Thu, 17 May 2012 20:22:21 +0000

End of Day, Cause and Effect EOD Commentary: RegMed stocks extended their losses, Thursday and again …remained … down … in volatile trading across the board. The VIX surged to above 23 from 22. How many times and ways to reiterate the … current … news … RegMed stocks had been under pressure [...]

Stem Speak … Levity and a “Hoodie” Comparison

Henry McCusker — Thu, 17 May 2012 19:07:54 +0000

Some levity to a lackluster day in the market as Facebook goes public and stem cell companies slide … Being that I was asked <multiple requests> to repost this … from a blog topic title: Referencing our sector: 5/14/12, What is the message of the market; blame it on the Greeks or start wearing a hoodie? [...]

RegMed Competitive and Market Intelligence 5/17/12, Dismal econ news and usual chaos in EU

Henry McCusker — Thu, 17 May 2012 17:34:46 +0000

The 6 W’s: Who, what, where, when, why and what of it Mid-Day: The NASDAQ is DOWN -21.66 (-0.75%) to 2,852.38 while the Dow is also DOWN -49.08 (-0.39%) to 12,549.47. Mid-Day Market Commentary: Some RegMed stocks opened higher (ASTM, CYTX, OSIR and STEM) but, struggled with … buoyancy … and keep struggling [...]

StemCells (STEM) Positive Interim Safety Data from Spinal Cord Injury Trial

Henry McCusker — Thu, 17 May 2012 13:54:52 +0000

Trial Proceeding to Enroll Patients with Incomplete Injury STEM completed the first planned interim safety review of the P1/2 spinal cord injury clinical trial, which indicated that the surgery, immunosuppression and the cell transplants have been well-tolerated. The trial, which is designed to evaluate the safety and preliminary efficacy of HuCNS-SC® cells (purified human [...]

RegMed Daily, Closing Bell, 5/15/12, If social networking is worth $100B; what is it worth to solve my heart muscle problem?

Henry McCusker — Wed, 16 May 2012 20:17:11 +0000

End of Day, Cause and Effect EOD Commentary: RegMed stocks were … down, Wednesday and again … remained choppy through out the day … in volatile trading across the board. The VIX surged to above 22. Stocks continued to waver in volatile trading Wednesday after investors digested the Fed’s latest meeting minutes and following [...]

RegMed Competitive and Market Intelligence 5/16/12, An analyst is an “expert” who will know tomorrow why the things he predicted yesterday … didn’t happen!

Henry McCusker — Wed, 16 May 2012 17:04:01 +0000

The 6 W’s: Who, what, where, when, why and what of it Mid-Day: The NASDAQ is now Down - 1.45 (-0.05%) to 2,892.31 while the Dow is UP +12.31 (+0.17%) to 12,653.31. Mid-Day Market Commentary: Some RegMed stocks opened higher (ASTM and OSIR) as others struggled to gain footage … in choppy trading Wednesday, as [...]

Earnings Report Card, Q1/12, Regenerative Medicine Universe

Henry McCusker — Wed, 16 May 2012 14:07:06 +0000

Report Card … so far An earnings release is a ‘report card’ of sorts for a public stem cell company. The current LPS (loss per share) standings reflect the universes’ investing status; then add in their cash position for a better snapshot! By analyzing these comparisons, investors can begin to gauge the financial health to [...]

BioMimetic (BMTI) Q1/12 Results and Highlights

Henry McCusker — Wed, 16 May 2012 13:27:59 +0000

Net loss of $6.1M, or $0.22 per share Net loss of $6.1M, or $0.22 per share compared to a net loss of $8M, or $0.28 per diluted share, for Q1/11. For Q1/12, BMTI reported total revenues of $0.5M consisting of sublicense fee income, royalty income and product sales. This compares to total [...]

International Stem Cell (OTC BB: ISCO) Q1/12 Results and Highlights

Henry McCusker — Wed, 16 May 2012 12:59:37 +0000

Net loss of $4.1M or $0.05 per share Net loss of $4.1M or $0.05 per share in Q1/12 is compared to a net loss of $1.7M or $0.02 in Q1/11. Revenues were $1.07M in Q1/12 compared to $1.5m in Q1/11. Cost of sales was $324K compared to $429K in Q1/11. R&D expenses [...]